Drug Profile
Research programme: antiviral therapeutics - Replicor/Institut National de la Recherche Scientifique
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Institut National de la Recherche Scientifique Institut Armand-Frappier; REPLICor
- Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Hepatitis-B in Canada
- 06 Nov 2017 Replicor and Institut National de la Recherche Scientifique agree to co-develop antiviral therapeutics in Canada for Hepatitis B and Hepatitis D
- 06 Nov 2017 Early research in Hepatitis B in Canada